AADAC Antikörper (AA 170-399)
Kurzübersicht für AADAC Antikörper (AA 170-399) (ABIN6136310)
Target
Alle AADAC Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- AA 170-399
-
Sequenz
- KKVLAKYGVN PERIGISGDS AGGNLAAAVT QQLLDDPDVK IKLKIQSLIY PALQPLDVDL PSYQENSNFL FLSKSLMVRF WSEYFTTDRS LEKAMLSRQH VPVESSHLFK FVNWSSLLPE RFIKGHVYNN PNYGSSELAK KYPGFLDVRA APLLADDNKL RGLPLTYVIT CQYDLLRDDG LMYVTRLRNT GVQVTHNHVE DGFHGAFSFL GLKISHRLIN QYIEWLKENL
-
Kreuzreaktivität
- Human, Maus
-
Produktmerkmale
- Polyclonal Antibodies
-
Aufreinigung
- Affinity purification
-
Immunogen
- Recombinant fusion protein containing a sequence corresponding to amino acids 170-399 of human AADAC (NP_001077.2).
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
- WB,1:500 - 1:2000,IHC,1:50 - 1:100
-
Kommentare
-
HIGH QUALITY
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Buffer
- PBS with 0.02 % sodium azide,50 % glycerol, pH 7.3.
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- Store at -20°C. Avoid freeze / thaw cycles.
-
-
- AADAC (Arylacetamide Deacetylase (Esterase) (AADAC))
-
Andere Bezeichnung
- AADAC
-
Hintergrund
- Microsomal arylacetamide deacetylase competes against the activity of cytosolic arylamine N-acetyltransferase, which catalyzes one of the initial biotransformation pathways for arylamine and heterocyclic amine carcinogens,AADAC,CES5A1,DAC,Cancer,Signal Transduction,Endocrine & Metabolism,Drug metabolism,AADAC
-
Molekulargewicht
- 45 kDa
-
Gen-ID
- 13
-
UniProt
- P22760
Target
-